Inozyme Pharma To Present Recently Announced Preliminary Data From Ongoing Phase 1/2 Trial In ENPP1 Deficiency At The European Calcified Tissue Society Congress
Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today